Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education



Front Page

World

UK

UK Politics

Business

Sci/Tech

Health

Education

Sport

Entertainment

Talking Point

In Depth

On Air

Archive
Feedback
Low Graphics
Help

Thursday, March 25, 1999 Published at 05:30 GMT


Aids drug trials underway

Up to 286,000 deaths from Aids are expected in Thailand by 2000

The first participants of the biggest Aids vaccine trial to be undertaken in a developing country have received their initial injections.

The Thai participants, the first of an expected 2,500 people to join the programme, received the jabs at a Bangkok medical centre on Wednesday.

Most of the volunteers are young male intravenous drug-users who are at high risk of HIV infection.


[ image:  ]
The vaccine being tested is produced by the California-based company VaxGen Incorporated, which also started the world's first trial of the vaccine in the US last June with a planned 5,000 volunteers.

Although about 30 possible Aids vaccines are being developed, VaxGen's is the only product which has reached so-called Phase III testing, which involves large-scale tests on human subjects.

Different vaccine

The vaccine being tested in Thailand is different from the product used in the US in order to match the different strains of HIV which prevail there.

The Thai trials, approved by the Thai ministry of health, are expected to cost between $6-9m.

They are being financed by VaxGen and some other US bodies with no Thai public money involved.

Preliminary results on the effectiveness of the vaccine will be available in 30 months, with the full study taking three or four years to complete.

Jose Esparza, the UN Aids vaccine team leader said: "We need to test different types of vaccines because we don't know which ones will work."

He described the trial as "very complex" logistically and ethically.

Foundation for future

Half the volunteers will get a placebo while the other half receive the actual vaccine. Participants will not know which group they fall into.

The experiment will help build the foundation for future clinical trials on vaccines in the developing world, UN Aids said.


[ image: Volunteers will get injections of vaccine or placebo]
Volunteers will get injections of vaccine or placebo
Other developing countries where Aids vaccine tests have been conducted include Cuba, Brazil and China.

Altogether some 30 different types of vaccines have been tested since 1987, mainly in the US, in phase I and II trials.

Some 16,000 people, mainly in the Third World, become infected with HIV every day.

Each year some $200m is spent on Aids vaccine research globally. Mr Esparza said this amount was "too low".

Developing countries spent more than that each year buying medicines to treat the deadly disease.



Advanced options | Search tips




Back to top | BBC News Home | BBC Homepage | ©



Relevant Stories

08 Feb 99 | Aids
Africa's first Aids vaccine trial starts

24 Dec 98 | Aids
More volunteers needed for Aids vaccine trials

21 Oct 98 | Asia-Pacific
Thailand's Aids crisis: Worst 'yet to come'





Internet Links


United Nations Aids programme

The Terrence Higgins Trust

AVERT - Aids education


The BBC is not responsible for the content of external internet sites.




In this section

Experts fight back against HIV threat

Experts tackling Asian AIDS explosion

Women demand HIV strategy

HIV expert warns of bloating side effect

Aids impact of Asia's economic crisis

Aids up close

UK millions fight Aids and polio

Inquiry begins into contaminated blood

UK faces new Aids fear

Parents fail to have baby tested for HIV

Drug-resistant HIV strains increasing

Aids success 'generates sex risks'

Aids statistics 'likely to be conservative'

African countries list Aids priorities

Battle against Aids 'will be slow'

Circumcision cuts HIV risk

Aids conference targets young men

'Scientists started Aids epidemic'

Babies risk HIV from breast milk

Baby in HIV court struggle

Russia 'on verge' of HIV epidemic

Aids drug hailed as 'major advance'

Aids Africa's top killer